AFT Pharmaceuticals - R&D pipeline strengthens with new candidate
AFT Pharmaceuticals has bolstered its R&D pipeline with the addition of a new product candidate, HY-090, a locally acting novel molecule,...
611 Views
AFT Pharmaceuticals - Global growth despite tough macro environment
AFT Pharmaceuticals reported solid H124 top-line growth, driven by strong momentum in the Asian and international markets. H124 revenues of...
218 Views
AFT Pharmaceuticals - 1H24 Result — Not Without Some Pain
The key positive was underlying non-ANZ sales growth of +95% versus 1H23, which, coupled with ongoing solid ANZ performance, more than offset gross...
370 Views
AFT Pharmaceuticals - FDA nod for opioid alternative, upside anticipated
AFT Pharmaceuticals announced FDA approval for Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine. The FDA...
438 Views
AFT Pharmaceuticals - FDA Pain Is Over
AFT Pharmaceuticals (AFT) has finally received the long awaited US FDA approval for its Maxigesic IV product (hospital-based product)
354 Views